Compare OXBR & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXBR | BRTX |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | Cayman Islands | United States |
| Employees | 4 | N/A |
| Industry | Property-Casualty Insurers | Managed Health Care |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.3M |
| IPO Year | N/A | 2015 |
| Metric | OXBR | BRTX |
|---|---|---|
| Price | $0.77 | $0.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | $80.09 | $438.78 |
| Revenue Next Year | $85.22 | $21.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.19 |
| 52 Week High | $2.85 | $2.04 |
| Indicator | OXBR | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 43.57 |
| Support Level | $0.76 | $0.23 |
| Resistance Level | $1.42 | $0.30 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 15.20 | 51.45 |
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer that provides reinsurance solutions through its subsidiary. The company focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. It specializes in underwriting medium-frequency, high-severity risks where insufficient data exists to effectively analyze the risk/return profile of reinsurance contracts. The company generates revenue from three principal sources: premiums assumed from reinsurance on property and casualty business; income from investments, including unrealized gains or losses on other investments; and income from SurancePlus management fees.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.